Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Clin Cancer Res. 2012 Dec 18;19(3):657–667. doi: 10.1158/1078-0432.CCR-11-1446

Figure 5. Combination of PLX4720 and a demethylating agent.

Figure 5

A. Cell lines were treated as indicated for 72 h. Combination therapy with 5-azacytidine and PLX4720 resulted in greater cytotoxicity than either treatment alone. (* P < 0.01 compared with PLX4720 alone) B. The combination of 5-azacytidine and PLX4720 demonstrates formal synergy for the four cell lines evaluated. C. HT29 and LS411N cells were treated with 5-azacytidine for 72 h before analysis. Phospho-AKT (S473), PTEN, and IGFBP-3 expression was assessed by immunoblot. D. Combination therapy with PLX4720 and 5-azacytidine demonstrates activity in HT29 xenografts. HT29 cells were pretreated with 1 µM 5-azacytidine or PBS (Control) prior to injection, followed by treatment of established tumor with PLX4720 chow, 5-azacytidine, or the combination, as described in the methods. Dual administration of PLX4720 and 5-azacytidine showed greater growth inhibition (TGI 83%) than either PLX4720 (TGI 55%, P<0.05) or 5-azacytidine alone (TGI 36%, P< 0.05).